Glimepiride is a sulfonylurea indicated for type 2 diabetes mellitus. We supply it to US manufacturers of tablets.
Data from PubChem (CID 3476) and FDA’s substance registry
CAS number
93479-97-1
Molecular formula
C24H34N4O5S
Molecular weight
490.6g/mol
FDA UNII
IUPAC name
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
InChIKey
WIGIZIANZCJQQY-UHFFFAOYSA-N
- Appearance
- White to almost white powder.
- Solubility
- Practically insoluble in water, soluble in dimethylformamide and sparingly soluble in methylene chloride.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
A low-dose, poorly soluble API. Micronized material is typical, and content uniformity depends on a tight particle size distribution.
On the US market
- Reference product
- AmarylNDA 020496
- Approved ANDAs
- 8 with a marketed product
- Approved forms and strengths
- Tablet 1 mg, 2 mg, 3 mg, 4 mg, 6 mg, 8 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com